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Background: To assess the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with either
unresectable locally advanced pancreatic adenocarcinoma or by locally recurrent disease after surgery.
Methods: Between January 2010 and October 2011, 30 patients with unresectable or recurrent pancreatic
adenocarcinoma underwent exclusive SBRT. Twenty-one patients (70%) presented with unresectable locally
advanced disease and 9 patients (30%) showed local recurrence after surgery. No patients had metastatic disease.
Gemcitabine-based chemotherapy was administered to all patients before SBRT. Prescription dose was 45Gy in
6 daily fractions of 7.5Gy. SBRT was delivered using the volumetric modulated arc therapy (VMAT) by RapidArc.
Primary end-point of this study was freedom from local progression (FFLP), secondary end-points were overall
survival (OS), progression free survival (PFS) and toxicity.
Results: Median Clinical Target Volume (CTV) was 25.6 cm3 (3.2-78.8 cm3) and median Planning Target Volume
(PTV) was 70.9 cm3 (20.4- 205.2 cm3). The prescription dose was delivered in 25 patients (83%), in 5 patients (17%) it
was reduced to 36Gy in 6 fractions not to exceed the dose constraints of organs at risk (OARs). Median follow-up
was 11 months (2–28 months). FFLP was 91% at 6 months, 85% at median follow-up and 77% at 1 and 2 years. For
the group with prescription dose of 45Gy, FFLP was 96% at 1 and 2 years. The median PFS was 8 months. The OS
was 47% at 1 year and median OS was 11 months. At the end of the follow-up, 9 patients (32%) were alive and 4
(14%) were free from progression. No patients experienced G ≥ 3 acute toxicity.
Conclusions: Our preliminary results show that SBRT can obtain a satisfactory local control rate for unresectable
locally advanced and recurrent pancreatic adenocarcinoma. This fractionation schedule is feasible, and no G ≥ 3
toxicity was observed. SBRT is an effective emerging technique in the multi-modality treatment of locally advanced
pancreatic tumors.
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Prognosis of pancreatic adenocarcinoma is still challenging,
because of occult and evident metastatic disease at the time
of diagnosis [1]. For those patients with no evidence of
distant metastasis, multimodality approach (surgery,
chemotherapy and radiotherapy) increase survival and
local control rates, thus improving quality of life [2].
Only 20% of the patients, however, are considered
suitable for surgery at the time of diagnosis, whereas
30-50% of the patients present with unresectable locally
advanced disease [3]. In the latter group, the only thera-
peutic option available is the concomitant chemo-radiation
treatment (CRT).
Unfortunately, despite the use of different schedules of
conventional radiation and concurrent chemotherapy,
local control rate after CRT is still relatively low, ranging
from 40% to 55%, with a median survival ranging from
5 to 14 months [4-6].
In the last years, innovations of radiation techniques
have promoted the use of hypo-fractionated regimens,
allowing to improve local control for lung and liver cancer
[7]. This trend has been also confirmed in other studies on
stereotactic body radiotherapy (SBRT) for locally advanced
pancreatic cancer, although with a higher incidence of
gastrointestinal toxicity, due to the radio-sensitivity of
normal organs of the upper abdomen, such as the
stomach and the duodenum [8-16].
The aim of this study was to analyse the feasibility and
the efficacy of hypo-fractionated SBRT in the setting




Between January 2010 and October 2011, 30 consecutive
patients with unresectable or recurrent pancreatic
adenocarcinoma were enrolled in this prospective,
single-institutional study.
Inclusion criteria were: 1) Histologically-proven unresect-
able primary or recurrent pancreatic adenocarcinoma, 2)
Neo-adjuvant chemotherapy 3) Age ≥18 years, 4) Karnofsky
Performance score of at least 70, 5) Lesions with maximum
diameter not exceeding 5 cm, 6) Ability to maintain the
set-up position during RT. Exclusion criteria were: 1)
Previous abdominal SBRT, 2) Metastatic disease, 3) Gastric
or duodenal obstruction, 4) Concurrent chemotherapy.
Stereotactic body radiation
Patients were immobilized in supine position with arms
over the head, using a thermoplastic body mask including
a styrofoam block for abdominal compression to minimize
internal organ motion (spontaneous or breath-induced). A
barium meal was administered to all patients about
15 mins before CT scan to enhance the stomach, theduodenum, and the small bowel. CT scan was performed
with a slice thickness of 3 mm and with and without non
iodinate contrast media.
The clinical target volume (CTV), defined as the gross
disease, was delineated on the arterial phase of CT scan.
An additional margin of 5 mm in the left-right direction,
5 mm in the anterior-posterior direction and 10 mm in
the cranial-caudal direction was added for the planning
target volume (PTV). The organs at risk (OARs) including
stomach, duodenum, kidneys, liver, and spinal cord,
were contoured and PTV was cropped so that there
was almost a 2 mm margin between the end of PTV
and the start of any stomach or duodenal tissue. The
dose-volume constraints for OARs were: duodenum:
D1cm3 < 36Gy; stomach and small bowels: D3cm3 < 36Gy;
kidneys: V15Gy < 35%; liver: total spared volume
(Vtot-V21Gy) > 700 cm
3; spinal cord: D1cm3 < 18Gy.
The prescription dose was 45Gy in 6 consecutive frac-
tions of 7.5Gy, the required target coverage was defined as
V95% = 100% for the CTV. The maximum acceptable dose
heterogeneity to the CTV was D98% > 95% and D2% < 107%.
For PTV the same objectives were ideally to be achieved
but with a lower priority than the constraints to the OARs.
Prescription dose was reduced to 36Gy in 6 fraction
of 6Gy in those cases where it was impossible to
comply with dose constraints of OARs.
SBRT plans were optimized and delivered according to
the volumetric modulated arc (VMAT) technique in its
RapidArc form. A beam energy of 6-10MV with flattened
or un-flattened (FFF) photon beams was selected for all
patients. Patients were treated either on a Clinac2100
or on a TrueBeam linear accelerator (Varian Medical
Systems, USA). Single or multiple coplanar partial
arcs were adopted according to dosimetric requirements.
Dose calculations were performed with the Anisotropic
Analytical Algorithm with a grid resolution of 2.5 mm.
RapidArc optimization was performed with the PROIII
algorithm (Eclipse version 10).
To reduce inter-fractional positioning problems, for all
patients, fasting was required at least 3 hours before the
treatment session to avoid the shift of stomach.
Image guidance was performed by means of Cone
beam CT imaging (CBCT) before every treatment
session to verify the exact position of the patient.
When necessary, couch repositioning was performed
after automatic matching of CBCT images to the reference
planning CT, followed by manual refining. Matching was
performed on bones and, when possible, on soft tissue
structures (e.g. main blood vessels).
Response evaluation and follow-up
Patients were re-evaluated 1 month after SBRT and then
every 3 months thereafter by the treating radiation
oncologist. Clinical examination, CA19-9 levels evaluation
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of the follow-up. A PET-CT scan was also performed
every 6 months after SRBT in those patients who had a
pre-SBRT staging PET-CT scan. Local control was defined
according to RECIST criteria [17] and by stable, decreasing,
or normalized CA 19-9 values. Acute and late toxicity was
scored according to the NCI Common Terminology
Criteria for Adverse Events (CTCAE) v3.0.
Statistical analysis
Actuarial local control and distant progression rates and
overall survival were calculated from the date of SBRT to
the date of progression and to the day of last follow-up or
death by using the Kaplan-Meier method. All enrolled
patients were included in the statistical evaluation.
Results
Patients and treatment characteristics
Thirty patients with pancreatic adenocarcinoma were
included in this study. Twenty-one patients showed
an unresectable disease invading vessels or adjacent
structures while 9 patients presented with local recurrence
after surgery. Patients characteristics are shown in Table 1.
Median follow up was 11 months (range 2-28 months).
Twenty-eight patients completed follow up, while two
patients were unavailable and considered lost to follow
up. Nine (32%) patients were alive at the time of analysis.
Median follow-up was 19 months in this group of patients
(range 13–28 months). The shortest follow up was due to
early death of the patients. All patients received pre-SBRTTable 1 Summary of patient characteristics
Patients number 30







Tumor location (number of patients):
Head 21 (70%)
Body / Tail 9 (30%)
Mean volume (range) [cm3]
CTV 25.6 (3.2-78.8)
PTV 70.9 (20.4-205.2)
Prior therapy (no. of patients)
Surgery 9 (30%)
Chemotherapy 30 (100%)
Radiation therapy 0 (0%)gemcitabine-based chemotherapy, completed 2 weeks
before SBRT at least. Ten of the patients (33%) received
Gemcitabine only, 11 patients (37%) were treated with
Gemcitabine-Oxaliplatinum (GEMOX), 7 patients (23%)
received Gemcitabine-5-Fluorouracil (GEM-5FU) and 2 pa-
tients (7%) received Cisplatinum-Epirubicin-Fluorouracil-
Gemcitabine (PEF-G). Chemotherapy cycles ranged
between 3 and 14.
Forty percent of patients (n = 12) had nodal disease at
time of diagnosis. Nine of these patients were treated with
surgery and enrolled in this study for local recurrence of
disease with no nodal involvement. In 3 patients with
inoperable locally advanced cancer, a complete regression of
nodal disease was achieved with pre-SBRT chemotherapy.
In these 3 patients, chemotherapy was also administered
after SBRT.
The radiation dose prescription was 45Gy in 6 fractions
in 25 patients (83%). In 5 patients (17%) the dose prescrip-
tion was reduced to 36Gy in 6 fractions not to exceed
dose constraints of duodenum and stomach. Median
CTV was 25.6 cm3 (range 3.2-78.8 cm3) and median
PTV was 70.9 cm3 (range 20.4-205.2 cm3).
Dosimetric features
Figure 1 shows the isodose distribution in axial, sagittal
and coronal views for one representative patient.
Color-wash was set in the range 80%-110% (36.0-49.5Gy).
Figure 2 shows the average cumulative Dose Volume
histograms computed over the full patient population
(a: CTV and PTV at 45Gy, b: CTV and PTV at 36Gy,
c: OARs irrespective of prescription). Dashed lines
correspond to the inter-patient variability expressed at
1 standard deviation. Table 2 summarizes the dosimetric
characteristics of the treatment plans derived from the
analysis of the DVHs. For target volume the table reports
only the findings for the sub-group treated at 45Gy. Similar
findings were obtained for the group treated at 36Gy but
are not reported because of the limited statistics.
Freedom from local progression (FFLP) and progression
free survival (PFS )
Local control was 86% (24/28 patients). Based on CT
assessment, partial response was observed in 7 patients
(25%), stable disease in 17 (61%), local progression occurred
in 4 patients (14%), no complete response was obtained. In
6 patients PET was available for follow up, 4 patients (67%)
showed complete response and 2 patients (33%) disease
local progression.
Disease progressive occurred in 20 patients; progression
free survival (PFS) is shown in Figure 3c. Median TTP,
considered as the median duration of survival free from
either local or distant progression calculated from the end
of SBRT, was 8 months. Median TTP calculated from
diagnosis was 14 months.
Figure 1 Example of dose distribution in axial, coronal and sagittal views for a representative patient. Color-wash thresholds are set to
80-110% (36-49.5 Gy).
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3 presented with unresectable diseases at diagnosis and 1
recurred after surgery. Time to progression was 5 months
in 2 cases (1 treated with 36 Gy and 1 treated with 45 Gy),
9 and 12 months in 1 case respectively, both treated with
36 Gy. Three patients died while 1 was alive at the last
follow-up.
Sixteen patients (57%) developed distant metastases.
Only 4 patients were alive at the last follow up.
The FFLP rate was 93% at 6 months, 86% at median
follow-up and 75% at 2 years (Figure 3a). A detailed analysis
of our results showed a FFLP rate of 96% at 1 and 2 years
in the group treated with a prescription dose of 45Gy with
a single case of local progression (Figure 3b).Overall survival (OS)
The overall survival calculated from SBRT was 67%
(95% CI: 0.5-0.8%) at 6 months and 47% (95% CI:
0.3-0.7%) at 1 year, with a median OS of 11 months
(Figure 3d). At last follow-up, 9 patients (32%) were
alive. Four patients (44%) presented with metastatic
disease, 1 patient (11%) presented with local progres-
sion and 4 patients (44%) were free from progression
as determined by stabilization of tumor markers with
stable CT. Median follow-up in the latter group was
22 months (range 19-28 months).Toxicity
Twelve patients (43%) experienced fatigue 4 weeks after
SBRT requiring no treatment (Grade 1). Five patients
(25%) suffered from nausea G1 while additional antiemetic
drugs (ondansetron) were administered to 3 (10%) patients
(G2). None of these patients had persistent nausea after
1 month. Three patients (10%) presented with pain G2.
There was no acute and/or late G3 toxicity. According to
the Numerical Rating Scale (NRS) scoring system, 11
(37%) patients experienced pain before SBRT. In 7
patients pain control after treatment allowed suspension
of analgesics administration; in 3 patients, analgesics
dosage was reduced by 50%, in 1 patient administration
was reduced by 20%.Discussion
Prognosis in patients with non-metastatic unresectable
locally advanced pancreatic cancer is worsened by the
inoperability judgment.
Chemotherapy alone reduces the incidence of distant
metastases in patients with localized disease, with a median
survival range of 9-14 months, even though it may hardly
improve disease local control [18,19].
This situation leads to a detriment of the quality of
life and the prognosis of this subset of patients, since
local progression highly increases the risk of severe
Figure 2 Average cumulative DVH over the patient population (solid line), inter-patient variability is expressed at 1 standard deviation
(dashed lines); a: CTV and PTV for patients treated at 36Gy; b: CTV and PTV for patients treated at 45Gy; c: OARs, irrespective of the
dose prescription.
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bleeding and chronic pain.
On the other hand the role of CRT in increasing the
local control is controversial, because of its limited efficacy.
The local progression rates reported with conventionally
fractionation of RT are 40–55% [4-6].
In the last years, the unsatisfying results of conventional
RT led to several studies which have investigated the
feasibility and efficacy of stereotactic techniques forthe treatment of pancreatic neoplasms. Recently, the
encouraging results of SBRT applied to primary and
secondary lesions of the lung and liver and other various
sites [7,17-24], indeed, promoted several studies on hypo-
fractionation technique in pancreatic cancer, as shown in
Table 3. Although many of these studies were performed
on a small cohort of patients whose characteristics were
not always homogeneous, improvement of local control
was relevant, with a success rate of 70-90% [8-16]. In the
Table 2 Summary of the DVH analysis for the CTV and
PTV (for the sub-group treated at 45Gy) and for the
organs at risk for the entire cohort of patients
Organ Parameter Objective Mean ± SD Range
CTV (45Gy) Mean [Gy] (45Gy) 45.0 ± 0.3 [44.2;45.8]
V95% [%] 100% 98.8 ± 3.9 [95.8;100.0]
D98% [%] >95% 95.5 ± 5.5 [93.0;102.2]
D2% [%] <107% 104.0 ± 1.3 [100.0;106.4]
PTV (45Gy) Mean (45Gy) 44.5 ± 0.6 [42.9;45.1]
Left Kidney Mean [Gy] - 3.8 ± 1.8 [0.5;7.7]
D1cm3 [Gy] - 9.6 ± 3.6 [2.2;16.8]
V15Gy [%] <35% 0.4 ± 1.0 [0.1;4.5]
Right Kidney Mean [Gy] - 4.3 ± 2.2 [0.8;10.4]
D1cm3 [Gy] - 11.8 ± 4.4 [4.4;23.8]
V15Gy [%] <35% 1.4 ± 3.9 [0.1;17.4]
Spinal Cord D1cm3 [Gy] <18Gy 9.5 ± 3.4 [5.4;17.9]
Duodenum D1cm3 [Gy] <36Gy 29.3 ± 8.5 [9.9;36.1]
Stomach Mean [Gy] - 2.8 ± 2.5 [0.1;8.4]
D3cm3 [Gy] <36Gy 10.2 ± 9.8 [0.2;25.3]
Small Bowel Mean [Gy] 6.7 ± 3.6 [0.5;14.6]
D3cm3 [Gy] <36Gy 16.1 ± 8.3 [2.3;26.5]
Liver Mean [Gy] - 1.8 ± 1.6 [0.3;6.0]
Vspare [%] Vtot–V21Gy >
700 cm3
1305 ± 290 [694;1716]
Data are reported as average values plus or minus standard deviation
and range.
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1 year and 80% at 2 years [12].
If we consider PFS and OS, data were comparable
to those obtained with the conventional fractionation.
In the study of Mahadevan et al. and Didolkar et al,
median OS was 20 and 18.6 months respectively, even
though these data were calculated from the diagnosis
and not from the SBRT treatment, as widely shown
in other experiences [14,15].
If on one hand SBRT is effective in improving
local control of unresectable pancreatic cancer, on
the other hand acute and late toxicity are still
challenging. The rate of late gastro-duodenal toxicity
G2 or greater varies from 10% and 50% in several
studies.
In our study all patients were treated for unresectable
locally advanced pancreatic adenocarcinoma, with a
prescription dose of 45Gy in 6 fractions in 85% of
patients. In 5 patients, however, prescription dose was
reduced to 36Gy in 6 fractions, as not to exceed dose
constraints at duodenum, stomach and small bowel.
We reported the FFLP rate of 85% at median follow-up
and 76% at 2 years. Particularly, in the group of 25patients treated with 45Gy, FFLP was 96%, at 1 and
2 years, confirming the efficacy of this fractionation,
especially when there is no need of a dose reduction.
Moreover there was no difference in the local control
between the patients treated with SBRT at diagnosis and
those treated for local recurrence after surgery, since
only 1 patient of the latter group presented with local
progression.
Another key-point of this study is the gemcitabine-
based chemotherapy before SBRT, although there is
no homogeneity of the adopted schedules. This
therapeutic strategy aims to control undetected dis-
tant micrometastases at the time of diagnosis and
treatment. Metastatic disease is the usual way of pro-
gression and also in our experience 80% of the 20
patients with progressive disease, presented with dis-
tant metastases. The median TTP calculated from
the start of SBRT and from the diagnosis was
8 months and 11 months, respectively. The median
OS calculated from the start of the treatment was
14 months, comparable to those results reported by
several studies in the literature [14,15].
Even if better local control does not improve
significantly the survival, it may reduce the risk of
gastric and biliary obstruction and other morbidities.
None of the patients free from local progression in
this study, indeed, showed any of these serious
complications.
Several previous experiences demonstrated that a
hypo-fractionated approach is more effective to treat
small size tumors. In our study, however, larger volumes
were treated with an optimal outcome, also with
regard to toxicity. For pancreatic RT, the presence of
near dose-limiting structures can be considered a
limit. Stereotactic regimens are associated with an
incidence of G ≥ 3 acute toxicity lower than with
conventionally fractionated radiation therapy [4-6],
but the late risk of ulcers and bleeding continues to
be significant with an incidence of 10-47% [10-12,14].
The biologically equivalent dose of our regimen is
superior to conventionally fractionated external beam
radiation, both for tumor and normal tissue toxicity,
but within the limits of tolerance for the gastrointes-
tinal tract. Unlike most of the other studies, our
immobilization system with thermoplastic body mask
including a Styrofoam block for abdominal compres-
sion, minimize the internal organ motion, reducing
the dose to OARs. We prioritized the duodenal and
stomach dose constraints so that the maximum dose
of 36Gy was not exceeded (Duodenum: D1% < 36Gy;
stomach: D3% < 36Gy). In 5 patients, this was not
possible because of the close contiguity of PTV and
the duodenum or the stomach and dose prescription
was reduced to 36Gy in 6 fractions. None of our
Figure 3 Actuarial analysis. a) Freedom from local progression for the entire cohort; b) Freedom from local progression for the patients treated
with 45Gy; c) Time to progression; d) Overall survival.
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types of acute or late toxicity G ≥ 3, confirming the safety
of this stereotactic body regimen. We feel that the high
conformity of dose with hotspots smaller than those
reported in other papers, allowed us to achieved this
optimal toxicity profile. Also, in all patients with pain at the
time of SBRT we obtained a reduction of the symptoms,
according to those reported in literature [8-16].Table 3 Summary of treatment regimen, local control, progre
recent study compared to the present study
Author, study
(ref.)
Patients (n) SBRT dose
(Gy/fraction)
CT gemcitabina-based
Koong [12] 15 15–25 Gy/1fx no
Hoyer [13] 22 45 Gy/3fx no
Schellenberg [14] 16 25 Gy/1fx sequential chemotherapy
Chang [15] 77 25 Gy/ 1fx For same patients prior CT
Schellenberg [16] 20 25 Gy/1fx sequential chemotherapy
Polistina [17] 33 30 Gy/3fx Prior chemotherapy
Didolkar [18] 85 15–30 Gy/3 fx sequential chemotherapy
Mahadevan [19] 39 24-36 Gy/3fx sequential chemotherapy
Rwigema [20] 71 18–25 Gy/1fx no
Present study 30 36-45Gy/6 fx Prior chemotherapy
Dx%: dose received by at least x% of the volume; Vx%: volume receiving at least x%In conclusion, within the limitations of a relatively
small sample size, this study demonstrated that SBRT is
an efficacy and safety therapeutic option to improve
local control in patients with unresectable advanced
pancreatic adenocarcinoma. Future studies are needed
to identify the best therapeutic strategy in combination
with systemic therapy to increase the impact on survival
for these patients.ssion free survival, overall survival and late toxicity in
FFLP (%) PFS (months) OS (months) GI toxicity
( ≥ G2) (%)
77% 2 11 from diagnosis none
57% 4.8 5.7 from diagnosis 18%
81% 9 11.4 from diagnosis 47%
84% - 11.4 from diagnosis 13%
94% 9.2 11.8 from diagnosis 20%
82.6% 7.3 10.6 none
91.7% - 18.6 from diagnosis
8.6 from SBRT
22%
85% 15 from diagnosis 20 from diagnosis 9%
64.8% - 10.3 10%
85% (96% for
group of 45 Gy)
8 from SBRT 14
from diagnosis
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